
    
      This randomized, double-blind, placebo-controlled, multicenter, 8-week, clinical trial is
      designed to assess the efficacy and safety of vilazodone and to discover genetic markers of
      treatment response associated with vilazodone use in adult patients diagnosed with MDD by the
      DSM-IV-TR criteria. This study will enroll approximately 400 patients.
    
  